Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Mlck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M, Moerch U
Vigorous shaking, touching the stopper with bare hands, or improper water use can lead to peptide degradation and inaccurate concentrations, which may result in side effects
Oral formulations will grow to capture 25% share as bioavailability improves and new small-molecule GLP-1s reach the market, appealing to segments seeking greater convenience or avoiding injection-site issues
Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor, Diabetes , 42/11, 1678-82.Back 'Ozempic predecessor suggests potential for GLP-1 drugs in Alzheimer's in early trial', CNN Health